The 6 most recent market catalysts affecting $SOBI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 65
European Commission Approves Sobi's Tryngolza for Severe Hypertriglyceridaemia
Sobi has received European Commission approval for Tryngolza (olezarsen) for severe hypertriglyceridaemia. This is a significant positive development for Sobi as it gains a new, fi…
Nov 10, 2026
Corporate Catalyst
Bearish
Impact 55
Deutsche Bank Research Downgrades Sobi to Hold
Deutsche Bank Research downgraded Swedish Orphan Biovitrum AB (Sobi) from a 'Buy' to a 'Hold' rating on November 10, 2026, while keeping its price target unchanged at SEK 515. This…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 65
Berenberg Raises Sobi Price Target Following Q3 Results
Investment bank Berenberg has raised its price target for Swedish Orphan Biovitrum AB (Sobi) to SEK 600 from SEK 570, while reiterating its 'buy' rating. This action is a direct re…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 85
Sobi Announces Positive Phase 3 REDUCE-2 Data for Pozdeutinurad
Sobi announced positive late-breaking Phase 3 data for its investigational gout drug, pozdeutinurad, at a major medical conference. The study demonstrated clinically meaningful and…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
Sobi Reports Q3 2026 Financial Results
Sobi has released its financial results for Q3 2026, reporting continued strong growth momentum, particularly within its rare disease therapy portfolio. This is a significant event…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
Sobi Raises Full-Year 2026 Revenue Growth Guidance
Sobi announced on October 27, 2026, that it has raised its revenue growth guidance for the full fiscal year 2026. This is a significant corporate catalyst as it indicates managemen…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.